# US 2021/0239685 A1 · Methods of analyzing dna in urine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0239685 A1
- Document ID: US20210239685A1
- Status: Published application
- Kind: A1
- Application number: 16/972,158
- Filed: 2019-06-27
- Published: 2021-08-05
- Earliest claimed: 2018-06-27
- Assignees: The Trustees of Indiana University
- Applicants: The Trustees of Indiana University
- Inventors: Tim LAUTENSCHLAEGER
- Web page: https://patentgrep.com/patent/US20210239685A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12N 15/1003: {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
- C12N 15/1017: {by filtration, e.g. using filters, frits, membranes}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/6869: Methods for sequencing
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 2800/54: Determining the risk of relapse
- G01N 2800/7028: Cancer
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates to methods of extracting DNA from urine and methods of analyzing DNA in a urine sample. Methods are provided for extracting ctDNA from a urine sample and analyzing the extracted ctDNA for mutations indicative of a disease. The disclosure also relates to compositions for use in such methods.

## Claims

### Claim 1

A method of detecting or monitoring circulating tumor DNA (ctDNA) in a patient urine sample comprising:
i. processing a patient urine sample to concentrate the sample;
ii. extracting the ctDNA from the sample; and
iii. analyzing the ctDNA in the sample wherein the ctDNA comprises short DNA fragment of less than 100 base pair (bp) in length.

### Claim 2 (depends on 1)

The method of claim 1, wherein the processing step comprises filtering the sample, dialyzing the sample, or combinations thereof

### Claim 3 (depends on 1)

The method of claim 1, wherein the processing step comprises urine crossflow diafiltration.

### Claim 4 (depends on 1)

The method of claim 1, further comprising neutralizing PCR inhibitors in the sample.

### Claim 5 (depends on 1)

The method of claim 1, further comprising removing the non-transrenal DNA from the sample.

### Claim 6 (depends on 1)

The method of claim 1, wherein processing the patient urine sample and extracting the ctDNA occur in the same step.

### Claim 7 (depends on 1)

The method of claim 1, wherein the urine sample is a sample that has been collected from a patient for about 24 hours.

### Claim 8 (depends on 1)

The method of claim 1, wherein the DNA is extracted using a size selectivity method.

### Claim 9 (depends on 1)

The method of claim 1, wherein the ctDNA is analyzed for mutations.

### Claim 10 (depends on 9)

The method of claim 9, wherein the mutation indicates a disease state in the patient.

### Claim 11 (depends on 10)

The method of claim 10, wherein the disease is cancer.

### Claim 12 (depends on 10)

The method of claim 10, wherein the disease is non-small cell lung carcinoma.

### Claim 13 (depends on 9)

The method of claim 9, wherein the ctDNA is analyzed by PCR.

### Claim 14 (depends on 13)

The method of claim 13 wherein the PCR is overlap extension PCR (OE PCR).

### Claim 15 (depends on 13)

The method of claim 13 wherein the PCR is digital droplet PCR (ddPCR) or emulsion PCR (EmPCR).

### Claim 16 (depends on 1)

The method of claim 1, wherein the ctDNA is analyzed for the presence of a tumor marker or a tumor recurrence marker.

### Claim 17 (depends on 1)

The method of claim 1, comprising monitoring the patient for cancer progression.

### Claim 18 (depends on 1)

The method of claim 1, comprising determining if the patient is eligible for a targeted cancer therapy.

### Claim 19 (depends on 11)

The method of claim 11, wherein the cancer is a non-metastatic cancer.

### Claim 20 (depends on 1)

The method of claim 1, wherein the extracted ctDNA comprisises short DNA fragment of about 30 to about 60 bp in length.
